BostonGene | LinkedIn (original) (raw)
``
Biotechnology
Waltham, MA 19,877 followers
Transforming Cancer Care: From Treating a Diagnosis to Treating the Person
About us
BostonGene is a biotechnology company specializing in advanced computational biology and precision medicine. Founded in 2015, BostonGene has consistently pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that drive precision medicine and advance oncology research.
Industry
Biotechnology
Company size
501-1,000 employees
Headquarters
Waltham, MA
Type
Privately Held
Founded
2015
Specialties
Bioinformatics, Medicine, Genomics, Immunooncology, Immunotherapies, biotech, pharma, and analytics
Locations
Employees at BostonGene
Updates
- Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene will deliver a keynote presentation at the European Federation of Laboratory Medicine Strategic Conference 2024 on Monday, September 23, outlining key strategies for implementing integrated diagnostics, with a focus on interdisciplinary collaboration, administrative alignment, and leveraging real-world data to enhance patient care and streamline payor negotiations.#EFLM #laboratorymedicine #IntegratedDiagnostics https://lnkd.in/eh3BxFFT
- We are excited to share that our research has been published in Nature! Our integrated multiomic molecular analysis uncovers key gene expression patterns and tumor evolution dynamics, providing insights that predict improved outcomes and reduced toxicity from combination therapy in patients with relapsed/refractory T-cell lymphomas. “Our findings offer a promising new approach for treating patients with relapsed and refractory T-cell lymphomas, specifically those with the follicular helper T-cell subtype. We are excited about the potential of this combination therapy to improve patient outcomes and expand treatment options in this challenging disease.” - Nathan Fowler, MD, Chief Medical Officer at BostonGene Congratulations to Ekaterina Postovalova, Nikita Kotlov, Alexander Bagaev Olga Kudryashova and all the contributing authors
- Attend our poster presentations at #ESMO24 to learn more about how BostonGene's comprehensive profiling reveals potential biomarkers and therapeutic targets that expand treatment options and support biomarker-driven clinical trials. Read more: https://lnkd.in/ebep_KwS
- We are proud to have received one Gold Stevie for our AI-based digital pathology platform and two Silver Stevies for our Tumor Portrait test and immune system profiling platform in the Stevie Awards for Technology Excellence, known as 'the Olympics for technology.' Read more: https://lnkd.in/ejtYrdax
- Attend today’s session, "Designing More Effective Trials with Integrated Immune Profiling of Peripheral Blood and Tumor Tissue", at the 14th Annual World CB & CDx Summit. "Immunotherapy holds transformative potential in oncology, but its success depends on our ability to match the right patients with the right therapies. Our AI-powered platform enables comprehensive immune system profiling to identify key immunological signatures and resistance factors, empowering clinicians to make personalized treatment decisions. Our ultimate goal is to improve patient outcomes by guiding therapies in real-time." - Michael Goldberg, PhD, VP, Research & Development at BostonGene.
- Join us next week in Boston for the 14th Annual World CB & CDx Summit, where we'll demonstrate our cutting-edge immune system profiling technology. Discover how we're advancing personalized immunotherapy and enabling real-time clinical decision-making.https://lnkd.in/gf5C4Dfk
- Meet us at next week at the 22nd Annual Conference of the Japanese Society for Digital Pathology. BostonGene's Chief Scientific Officer, Joe Lennerz, MD, PhD, will lead a session on the evolving landscape of digital pathology and present two abstracts on AI-based imaging analysis technologies to improve patient care.https://lnkd.in/eZP7ck-3
- BostonGene reposted this
We are pleased to enter a new partnership with BostonGene, a leading provider of #ArtificialIntelligence (AI)-driven molecular and immune profiling solutions. This partnership will enable us to use cutting-edge technology to better understand our investigational therapies at the earliest stages, optimizing their development for people living with #cancer. Find out more: https://lnkd.in/g3kJes6f
Join now to see what you are missing
Similar pages
Browse jobs
- Talent Acquisition Specialist jobs 35,355 open jobs
- Senior Director jobs 149,969 open jobs
- Director jobs 1,374,979 open jobs
- Recruiter jobs 321,337 open jobs
- Specialist jobs 849,142 open jobs
- Legal Recruiter jobs 5,916 open jobs
- Bioinformatics Scientist jobs 960 open jobs
- Computational Biologist jobs 1,075 open jobs
- Account Manager jobs 152,491 open jobs
- Executive jobs 700,389 open jobs
- Talent Acquisition Manager jobs 18,513 open jobs
- Senior Vice President Business Development jobs 2,939 open jobs
- Electronic Technician jobs 42,370 open jobs
- Medical Director jobs 55,579 open jobs
- Director Medical Affairs jobs 5,128 open jobs
- Project Manager jobs 312,603 open jobs
- Science Specialist jobs 15,173 open jobs
- Talent Director jobs 18,828 open jobs
- Assistant jobs 728,748 open jobs
- Academic jobs 326,002 open jobs